Central role of the P2Y12 receptor in platelet activation

Journal of Clinical Investigation

Volumn 113, Issue 3, 2004, Pages 340-345

  Dorsam, Robert T ^a   Kunapuli, Satya P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PURINE P2 RECEPTOR;

BLEEDING; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; THROMBOCYTE ACTIVATION; BLEEDING TIME; BLOOD CLOTTING; HUMAN; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; HUMANS; MEMBRANE PROTEINS; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2;

EID: 85047693299     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20986     Document Type: Review

References (53)

1. Jackson, S.P., Nesbitt, W.S., and Kulkarni, S. 2003. Signaling events underlying thrombus formation. Thromb. Haemost. 1:1602-1612.
2. Kunapuli, S.P., et al. 2003. ADP receptors: targets for developing antithrombotic agents. Curr. Pharm. Des. 9:2303-2316.
3. Paul, B.Z., et al. 2003. Dynamic regulation of microtubule coils in ADP-induced platelet shape change by p160ROCK (Rho-kinase). Platelets. 14:159-169.
4. Kahn, M.L., Nakanishi-Matsui, M., Shapiro, MJ., Ishihara, H., and Coughlin, S.R. 1999. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103:879-887.
5. Brass, L.F., Manning, D.R., Cichowski, K., and Abrams, C.S. 1997. Signaling through G proteins in platelets: to the integrins and beyond. Tbromb. Haemost. 78:581-589.
6. Shattil, S.J., Kashiwagi, H., and Pampori, N. 1998. Integrin signaling: the platelet paradigm. Blood. 91:2645-2657.
7. Cattaneo, M., and Gachet, C. 1999. ADP receptors and clinical bleeding disorders. Arterioscler. Thromb. Vasc. Biol. 19:2281-2285.
8. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 348:1329-1339.
9. Dangelmaier, C., Jin, J., Smith, J.B., and Kunapuli, S.P. 2001. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Tbromb. Haemost. 85:341-348.
10. Jin, J., and Kunapuli, S.P. 1998. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. U. S. A. 95:8070-8074.
11. Dorsam, R.T., Kim, S., Jin, J., and Kunapuli, S.P. 2002. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J. Biol. Chem. 277:47588-47595.
12. Quinton, T.M., et al. 2002. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem. J. 368:535-543.
13. Kauffenstein, G., et al. 2001. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin: a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 505:281-290.
14. Nieswandt, B., Schulte, V., Zywietz, A., Gratacap, M.P., and Offermanns, S. 2002. Costimulation of Gi- and G12/G13-mediated signaling pathways reduces integrin alpha IIbbeta 3 activation in platelets. J.B Biol. Chem. 277:39493-39498.
15. van Gestel, M.A., et al. 2003. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler. Thromb. Vasc. Biol. 23:518-523.
16. Andre, P., et al. 2003. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J. Clin. Invest. 112:398-406. doi:10.1172/JCI200317864.
17. Kunapuli, S.P., Dorsam, R.T., Kim, S., and Quinton, T.M. 2003. Platelet purinergic receptors. Curr. Opin. Pharmacol. 3:175-180.
18. Gachet, C. 2001. ADP receptors of platelets and their inhibition. Thromb. Haemost. 86:222-232.
19. Hollopeter, J., et al. 2001. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 409:202-207.
20. Zhang, F.L., et al. 2001. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J. Biol. Chem. 276:8608-8615.
21. Ohlmann, P., et al. 2000. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood. 96:2134-2139.
22. Jin, J., Quinton, T.M., Zhang, J., Rittenhouse, S.E., and Kunapuli, S.P. 2002. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood. 99:193-198.
23. Zhao, L., Bath, P., and Heptinstall, S. 2001. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br. J. Pharmacol. 134:353-358.
24. Storey, R.F., Judge, H.M., Wilcox, R.G., and Heptinstall, S. 2002. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb. Haemost. 88:488-494.
25. Daniel, J.L., Dangelmaier, C., Jin, J., Kim, Y.B., and Kunapuli, S.P. 1999. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb. Haemost. 82:1322-1326.
26. Yang, J., et al. 2000. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc. Natl. Acad. Sci. U. S. A. 97:9984-9989.
27. Hirsch, E., et al. 2001. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J. 15:2019-2021.
28. Chrzanowska-Wodnicka, M., Schoenwaelder, S., and White, G.C., II. 2003. Rap1b regulates integrin IIb3 activity and platelet function: lessons from a knockout. Blood. 102:773a. (Abstr.)
29. Shankar, H., et al. 2003. Role of G-protein coupled inwardly rectifying potassium channels (GIRKs) in P2Y12 receptor-mediated platelet functional responses. Blood. 102:774a. (Abstr.)
30. Woulfe, D.S., et al. 2003. Mice lacking Akt2 have defects in platelet granule secretion and fibrinogen binding and reduced thrombus formation in vivo. Blood. 102:207a. (Abstr.)
31. Kim, S., Jin, J., and Kunapuli, S.P. 2004. Akt activation in platelets depends on Gi signaling pathways. J. Biol. Chem. In press.
32. Nurden, P., et al. 1995. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J. Clin. Invest. 95:1612-1622.
33. Cattaneo, M., Lecchi, A., Randi, A.M., McGregor, J.L., and Mannucci, P.M. 1992. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 80:2787-2796.
34. Cattaneo, M., Lecchi, A., Lombardi, R., Gachet, C., and Zighetti, M.L. 2000. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler. Thromb. Vasc. Biol. 20:E101-E106.
35. Cattaneo, M., et al. 2003. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc. Natl. Acad. Sci. U. S. A. 100:1978-1983.
36. Foster, C.J., et al. 2001. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J. Clin. Invest. 107:1591-1598.
37. Cattaneo, M., et al. 1997. Deficiency of (P-33)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that Adp potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb. Haemost. 77:986-990.
38. Conley, P.B., and Delaney, S.M. 2003. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr. Opin. Hematol. 10:333-338.
39. Bennett, J.S. 2001. Novel platelet inhibitors. Annu. Rev. Med. 52:161-184.
40. Savi, P., et al. 2001. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 283:379-383.
41. Takasaki, J., et al. 2001. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol. Pharmacol. 60:432-439.
42. Remijn, J.A., et al. 2002. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb. Vasc. Biol. 22:686-691.
43. Turner, N.A., Moake, J.L., and McIntire, L.V. 2001. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 98:3340-3345.
44. Goto, S., Tamura, N., Eto, K., Ikeda, Y., and Handa, S. 2002. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP 1balpha induced by conditions of high shear rate. Circulation. 105:2531-2536.
45. Mitka, M. 2001. Results of CURE trial for acute coronary syndrome. JAMA. 285:1828-1829.
46. Hacke, W. 2002. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc. Dis. 13:22-26.
47. Bennett, C.L., et al. 2000. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. 342:1773-1777.
48. Clarke, T.A., and Waskell, L.A. 2003. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 31:53-59.
49. Lau, W.C., et al. 2003. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 107:32-37.
50. Saw, J., et al. 2003. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 108:921-924.
51. Wienbergen, H., et al. 2003. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am. J. Cardiol. 92:285-288.
52. Lenain, N., Freund, M., Leon, C., Cazenave, J.P., and Gachet, C. 2003. Inhibition of localized thrombosis in P2Y1-deficient mice and todents treated with MRS2179, a P2Y1 receptor antagonist. J. Thromb. Haemost. 1:1144-1149.
53. Wang, K., et al. 2003. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler. Thromb. Vasc. Biol. 23:357-362.